Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report.

doi:10.3389/fimmu.2022.1047992

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report.

Frontiers in immunology - 1 Jan 2022

Zhang Weihe, Jiao Yujuan, Jiao Jinsong, Jin Ming, Peng Dantao

Abstract excerpt

Background: Elderly-onset neuromyelitis optica spectrum disorder (NMOSD) is a rare entity that poses a therapeutic challenge. We report a case of elderly-onset NMOSD with mutant FCGR3A genotype who was successfully treated with ofatumumab after multiple episodes of relapse. Case Report: The patient was a 67-year-old woman who was diagnosed with NMOSD with high disease activity. She experienced six episodes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinemia
Share to Immunoglobulins, Intravenous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Immunosuppressive Agents

Share to Neuromyelitis Optica

Share to Receptors, IgG

Share to Recurrence

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 36569904
DOI: 10.3389/fimmu.2022.1047992
PMCID: PMC9773878

Provenance

PubMed metadata and Literature Corpus relationships.